Skip to main content

Table 2 Patient baseline characteristics by level of compliance

From: Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study

  High (≥80%) Low (<80%) pvalue
Demographics    
 Age, years, mean (SD) 43.0 (12.8) 43.8 (12.9) 0.44
 Weight, kg, mean (SD) 73.5 (13.8) 73.9 (14.1) 0.69
 Height, cm, mean (SD) 168.1 (9.3) 167.1 (8.8) 0.11
 Sex, females, n (%) 337 (56.7) 176 (59.3) 0.47
Race, n (%)    0.30
 Caucasian 384 (65.1) 198 (67.3)  
 Hispanic 37 (6.3) 24 (8.2)  
 East Asian 169 (28.6) 72 (24.5)  
Clinical characteristics    
 CGI-S, mean (SD) 2.4 (0.7) 2.6 (0.7) 0.002
 DAI-10, mean (SD) 5.7 (3.7) 4.8 (4.0) 0.002
 Days bipolar inpatient last year, mean (SD) 15.4 (38.5) 18.4 (32.8) 0.029
 Recent relapse, n (%) 68 (11.4) 68 (22.9) <0.001
Functional characteristics    
 EQ-5D overall health status score (SD) 0.9 (0.2) 0.8 (0.2) 0.0012
 EQ-5D VAS score (SD) 74.2 (15.4) 69.6 (17.6) <0.001
 Number of activities with friends or social groups, n (%)    
  0 100 (16.8) 85 (29.0)  
  1 66 (11.1) 40 (13.7) <0.001
  2 117 (19.7) 49 (16.7)  
  3 78 (13.1) 40 (13.7)  
  4 70 (11.8) 20 (6.8)  
  ≥5 163 (27.4) 59 (20.1)  
 Work activity, n (%)    
  Unable to work 34 (5.8) 26 (9.0) <0.001
  Volunteer work 21 (3.6) 6 (2.1)  
  Student 34 (5.8) 12 (4.1)  
  Working for pay 199 (33.8) 76 (26.2)  
  Keeping house 109 (18.5) 48 (16.6)  
  Unemployed 59 (10.0) 23 (7.9)  
  Sheltered program 15 (2.5) 3 (1.0)  
  Retired 118 (20.0) 96 (33.1)  
 Impairment in work activities, n (%)    
  No impairment 123 (20.8) 39 (13.3)  
  Mild impairment 220 (37.2) 81 (27.6)  
  Moderate impairment 150 (25.4) 133 (45.2)  
  Severe impairment 50 (8.5) 22 (7.5)  
  Unable to work due to mental illness 31 (5.2) 15 (5.1) <0.001
 Patient-physician relationship, n (%)    
  Poor 0 7 (2.4) <0.001
  Fair 20 (3.4) 25 (8.4)  
  Good 158 (26.6) 148 (49.8)  
  Very good 277 (46.6) 101 (34.0)  
  Excellent 139 (23.4) 16 (5.4)  
 Insight into illness, n (%)    
  None 3 (0.5) 3 (1.0)  
  Low 26 (4.4) 49 (16.5) <0.001
  Medium 87 (14.6) 111 (37.4)  
  Moderate 168 (28.3) 93 (31.3)  
  High 310 (52.2) 41 (13.8)  
 Length of previous treatment regimen (4 weeks before baseline, containing olanzapine), n (%)    
  <14 days 8 (1.3) 10 (3.5)  
  15 to 30 days 125 (21.1) 91 (31.5) <0.001
  31 to 90 days 212 (35.8) 77 (26.6)  
  >90 days 244 (41.1) 101 (34.9)  
  1. CGI-S, Clinical Global Impression of Severity; DAI-10, Drug Attitude Inventory - short version; EQ-5D, European Quality of Life instrument-5 dimensions; SD, standard deviation; VAS, visual analog scale.